Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHARP: Ayurvedic SUVED & Reimmugen for Vascular Disease
NCT02920125Phase 3Completed
- Start
- Jan 2016
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vascular disease, coronary artery disease (CAD), cerebrovascular accident (CVA) and 3 more comparing Suved + Reimmugen with Placebo (2 arms). Primary endpoint: Intima-Media Thickness at 3 months. Started Jan 2016; status: completed.
02
Drugs
bovine colostrum
03
Conditions
vascular diseasecoronary artery disease (CAD)cerebrovascular accident (CVA)ischemic heart disease (IHD)deep vein thrombosis (DVT)
Beyond the preview
Go deeper on NCT02920125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920125.